BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 10070926)

  • 1. Intravenous iron supplementation in end-stage renal disease patients.
    Matzke GR
    Am J Kidney Dis; 1999 Mar; 33(3):595-7. PubMed ID: 10070926
    [No Abstract]   [Full Text] [Related]  

  • 2. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
    Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
    Kaskel FJ
    Nat Clin Pract Nephrol; 2006 May; 2(5):244-5. PubMed ID: 16932433
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin.
    Harmankaya O; Eran A
    Ren Fail; 2002 Mar; 24(2):245-7. PubMed ID: 12071600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium ferric gluconate complex therapy in anemic children on hemodialysis.
    Warady BA; Zobrist RH; Wu J; Finan E;
    Pediatr Nephrol; 2005 Sep; 20(9):1320-7. PubMed ID: 15971073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving target hematocrit in dialysis patients: new concepts in iron management.
    Nissenson AR
    Am J Kidney Dis; 1997 Dec; 30(6):907-11. PubMed ID: 9398140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of available intravenous iron preparations in hemodialysis.
    Palmer K; Cameron K; Battistella M
    CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of two iron gluconate treatment modalities in chronic hemodialysis patients: results of a randomized trial.
    Giordano A; Arrigo G; Lavarda F; Colasanti G; Petrini C
    J Nephrol; 2005; 18(2):181-7. PubMed ID: 15931646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementing continuous quality improvement strategies for improving iron replacement in hemodialysis patients.
    Trenkle JA
    Nephrol Nurs J; 2001 Oct; 28(5):561-5. PubMed ID: 12143432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
    Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
    J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Factors influencing responsiveness to treatment in children with renal anemia in end stage renal disease].
    Haliţchi CI; Munteanu M; Brumariu O
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(1):94-9. PubMed ID: 18677909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Iron supplementation in chronic kidney disease].
    Graczyk M; Dylewska M
    Wiad Lek; 2017; 70(6 pt 2):1215-1218. PubMed ID: 29533917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current recommendations for the treatment of iron deficiency anemia].
    Schaefer RM; Huch R; Krafft A;
    Rev Med Suisse; 2007 Apr; 3(105):874-80. PubMed ID: 17514929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of intravenous iron therapy on novel markers of iron deficiency.
    Chinnappa S; Bhandari S
    Int J Artif Organs; 2010 May; 33(5):297-301. PubMed ID: 20593351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron supplementation in haemodialysis--practical clinical guidelines.
    Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
    Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
    Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
    Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron.
    Trivedi HS; Brooks BJ
    Am J Nephrol; 2003; 23(2):78-85. PubMed ID: 12481145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
    Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
    Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron replacement in rHuEPO-treated dialysis patients: DOQI and beyond.
    Mittman N
    Am J Kidney Dis; 1999 Jul; 34(1):173-6. PubMed ID: 10401035
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.